Marianne Boes

dr.

    1998 …2024

    Research activity per year

    Personal profile

    Personal webpage

    Biography

    Marianne Boes heads the pediatric immunology laboratory at the UMC Utrecht, embedded in the Center for Translational Immunology. Her team focuses on approaches for harnessing the strength of the immune response and its promise to redirection using immune response modification, as preventive or therapeutic medicine. Boes trained in the USA in immunology and cell biology research (1996-2008). She performed PhD research at Massachusetts Institute of Technology (MIT), at the Koch Institute for integrative Cancer Research under supervision of prof. Jianzhu Chen. Here she studied immunodeficiency mechanisms using mouse models. Postdoctoral work she performed at Harvard Medical School in the laboratory of prof. Hidde Ploegh.

    In 2004, Dr. Boes started her independent research lab at Brigham and Women’s Hospital/Harvard Medical School, financed in part by an NWO-Veni grant in 2004 and a large NIH-RO1 grant that was awarded to her.  She is the founding chair of the Young Academy of the UMC Utrecht (chair Sept 2019-Jan 2022) and board member of the CUCo working group of the Young Academies of the Strategic Alliance between TU-Eindhoven, Wageningen, Utrecht University and UMC-Utrecht, 2019-2022. Boes serves as coordinator of the course 'Advanced Immunology' and van Kinsbergen Advanced+ Immunology for PhD students. She is current member of the I&I graduate school teaching committee and the Board of Examiners, subcommittee Assessment Support Panel (ASP) @ GSLS-life Sciences Academy. She thoroughly enjoys to meet and learn from researchers, patients and societal partners in different fields. 

    Side activities

    Scientific Advisory Board Member at Dutch Diabetes Research Foundation (Diabetes Fonds), June 2022-May 2026 (no payment)

    Clinical Fellows program at ZonMw, vice-chair, 2019-current (< €1000)

    IDSCOVA mRNA vaccination study LUMC (Establishing the tolerability, safety and immunogenicity of intradermal delivery of a mNRA SARS-CoV-2 vaccine in healthy adults), DSMB member, 2020-2021 (no payment)

    Immunotherapy Advances (Oxford Academic Press), deputy-editor: 2019-current (< €1000)

    Immunology Letters (Elsevier), section editor: 2022-current (< €1000)

     

    Fellowship & awards

     

    Jan 2024 - Dec 2028: Horizon-HLTH CLARITY: 7 million euro/5 years (coordinator of consortium and PI)

    2021-2023: EWUU-Unusual Collaboration grant; ±160K euro/yr (co-PI)

    2022: PhD incentive Radboud University / UMC Utrecht, 270 KEuro (PI)

    2021: Actuate grant 200K dollar (PI)

    2019: Lymph&co 385K (PI)

    2018: Nutricia 47.5K (co-PI)

    2015: UU Life Sciences Seed grant 100K (co-PI)

    2014: NWO-PhD grant 250K (I&I graduate school UU)

    2014: Diabetes Fonds Nederland 250K (co-PI)

    2010: ERC-Marie Curie 80K (PI)

    2007: NIH-RO1 grant 750K (PI)

    2004: NWO-Veni 250K (PI)

    2001: Cancer Research Institute/ Irvington fellowship 300K (PI)

    1997: Boehringer Ingelheim PhD fellowship 250K (PI)

     

     

     

     

     

     

     

     

     

     

     

    Education/Academic qualification

    Postgraduate, Governance opleiding voor commissarissen & bestuurders

    Award Date: 22 Dec 2022

    IUS Promovendi

    31 Jan 20191 Jan 2099

    Award Date: 21 Jan 2019

    Unknown, certificate teaching degree in higher education (Basic): BKO

    24 Jan 20181 Jan 2099

    Award Date: 24 Jan 2018

    Keywords

    • Q Science (General)
    • R Medicine (General)

    Collaborations and top research areas from the last five years

    Recent external collaboration on country/territory level. Dive into details by clicking on the dots or